42 research outputs found
Against the masses varieties of anti-democratic thought since the French Revolution
No full text"The author attempts to combat collective amnesia by systematically exploring and evaluating anti-democratic thought since the French Revolution. Femia examines the various arguments under the headings of 'perversity', 'futility', and 'jeopardy'. This classification scheme enables him to highlight the fatalism and pessimism of anti-democratic thinkers, their conviction that democratic reform would be either pointless or destructive. Femia shows how they failed to understand the adaptability of democracy, its ability to co-exist with traditional and elitist values. But, controversially, he also argues that some of their predictions and observations have been confirmed by history."--BOOK JACKET
The author as actor: a defense of Quentin Skinner
No full textIn this thesis, I defend Quentin Skinner's work against some criticisms raised by three of his interlocutors: John Keane, Kennet Minogue, and Joseph Femia. All three of these critics take issue with Skinner's author-centered approach to the historical interpretation of texts. Femia, invoking Roland Barthes 'death of the author' thesis, argues that Skinner's attempt to recover the intentions of authors is impossible. While Minogue and Keane do not dispute the possibility of recovering an author's intentions, they question the unity of such an enterprise. In order to answer Femia's criticism of Skinner, I draw an analogy between Skinner's figure of the author, and Arendt's figure of the political actor. I argue that just as it is possible for someone to know what a political actor is doing in performing a political act, it is similarly possible for an intellectual historian to understand what political acts an author was doing in writing his or her text. To refute Minogue's and Keane's claims that a Skinnerian approach to intellectual history is of no use to the political theorist, I point to three examples of how Skinner's recovery of forgotten political discourses have been applied to contemporary debates in political theory.Graduat
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
No full textIn the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs. In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up
No full textWe report the case of a 38-year-old patient who was diagnosed with a cerebellar well-differentiated neuroendocrine tumor (WDNET) in 2009. At first glance, we believed that it was a metastasis from an unrecognized WDNET arising outside the cerebellum. However, despite a prolonged follow-up of 6 years, an extracranial WDNET has never been found. During this time, the tumor recurred locally twice, and the patient was treated with surgery and radiotherapy. At the moment, he enjoys good general conditions and his tumor is under control. Due to the histopathological characteristics and clinical behavior of the tumor, we believe that this is the first report to date of a primary cerebellar WDNET
Everolimus treatment for neuroendocrine tumors: Latest results and clinical potential
No full textNeuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs. Everolimus is a direct inhibitor of this pathway, and therefore this molecule appears to be a well-grounded strategy for the treatment of NETs, capable of changing clinical practice. The efficacy and safety of everolimus was demonstrated in the RADIANT trials. In this work, we comment on the results of the RADIANT trials, and other recent key evidence from fully published clinical trials on everolimus, and we discuss the current role of everolimus in the treatment of NETs
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors
No full textMetformin (MET) has recently emerged as a potentially active agent in cancer prevention and treatment. MET is thought to exert its antitumor effects either via modification of systemic metabolism or through cell-autonomous effects (e.g., activation of AMPK and inhibition of the mTOR pathway). Preliminary findings of the PRIME-NET study suggest that the addition of MET to treatment with everolimus (EVE) and/or somatostatin analogs (SSAs) can provide clinical benefit in diabetic neuroendocrine tumor (NET) patients. In light of this and other retrospective evidence of MET’s anticancer activity in NETs, prospective studies are needed.
A pilot, single-arm, open-label, prospective study (MetNET-2 trial, NCT02823691) was designed to evaluate the safety of MET in combination with lanreotide in well-differentiated gastrointestinal (WD GI) and lung NETs
A visual demonstration of supramolecular chemistry: observable fluorescence enhancement upon host-guest inclusion
No full textPT: J; CR: BOZZELLI JW, 1982, J CHEM EDUC, V59, P787 BRESLOW R, 1998, J CHEM EDUC, V75, P705 BUCCIGROSS JM, 1996, J CHEM EDUC, V73, P275 BURROWS HD, 1983, J CHEM EDUC, V60, P228 CATENA GC, 1989, ANAL CHEM, V61, P905 CONN MM, 1997, CHEM REV, V97, P1647 CONRADI S, 1997, J CHEM EDUC, V74, P1122 CRAM DJ, 1992, NATURE, V356, P29 CRAMER F, 1967, J AM CHEM SOC, V89, P14 DIEDERICH F, 1990, J CHEM EDUC, V67, P813 EBBESEN TW, 1989, J PHYS CHEM-US, V93, P7139 FEMIA RA, 1985, ENVIRON SCI TECHNOL, V19, P155 FYFE MCT, 1997, ACCOUNTS CHEM RES, V30, P393 HAMILTON AD, 1990, J CHEM EDUC, V67, P821 KONDO J, 1976, J BIOCH, V79, P393 LACKOWICZ JR, 1983, PRINCIPLES FLUORESCE, CH7 LEHN JM, 1988, ANGEW CHEM INT EDIT, V27, P89 LERNER DA, 1989, ANAL CHIM ACTA, V227, P297 LI S, 1992, CHEM REV, V92, P1457 WAGNER BD, 1998, J PHOTOCH PHOTOBIO A, V114, P151 ZARZYCKI PK, 1996, J CHEM EDUC, V73, P459 ZIESSEL RF, 1997, J CHEM EDUC, V74, P673; NR: 22; TC: 6; J9: J CHEM EDUC; PG: 4; GA: 274KQSource type: Electronic(1
Update on medical treatment of small intestinal neuroendocrine tumors
No full textIntroduction: Small intestinal (SI) neuroendocrine tumors (NETs) are relatively rare tumors. Due to the lack of symptom or specific symptoms, SI-NETs are often diagnosed at an advanced stage, making therapy challenging. The management of patients with advanced stage SI-NETS requires a multidisciplinary approach that combines surgical and medical treatment including novel targeted molecular therapies.
Areas covered: This article summarizes current strategies for the medical treatment of SI-NETS.
Expert commentary: The treatment plan of advanced-stage SI-NETs should be tailored in a case-bycase manner with the adoption of a multidisciplinary approach that combines different treatment options, including biological targeted therapies. In particular, we believe that the identification of the optimal treatment sequence(s), correct treatment timing and the selection of patients eligible to different treatments need specific investigation in controlled clinical trials
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes
No full textA bidirectional relationship seems to exist between diabetes mellitus and development of pancreatic tumors. Metformin, the most widely used drug in the treatment of Type 2 diabetes mellitus, has recently emerged as a potentially active agent in cancer chemoprevention and treatment. In this article, we discuss the potential correlation between glycemic status, administration of antiglycemic treatments, such as metformin or insulin, and prognosis of pancreatic neuroendocrine tumors patients treated with everolimus and octreotide, on the basis of existing evidence and our experience
